JCM
TVRD

Jag Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Jag Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-312
Closed -$3.46K – 151
2024
Q3 		$3.46K Hold
312
– – ﹤0.01% 141
2024
Q2 		$2.9K Hold
312
– – ﹤0.01% 136
2024
Q1 		$10.2K Hold
312
– – ﹤0.01% 136
2023
Q4 		$8.35K Hold
312
– – ﹤0.01% 132
2023
Q3 		$18.9K Hold
312
– – ﹤0.01% 175
2023
Q2 		$31.8K Buy
+312
New +$43K ﹤0.01% 178

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jag Capital Management's TVRD Position: Q4 2024 in Review

Jag Capital Management sold out of Tvardi Therapeutics (TVRD) in Q4 2024, closing a stake of 312 shares — an estimated $3.46K sold.

Jag Capital Management first reported a position in TVRD in Q2 2023 and held it in 6 quarters. The position peaked at $31.8K in Q2 2023. 43 funds tracked by Wall St. Rank hold TVRD as of Q4 2024.

  • Jag Capital Management reported no remaining Tvardi Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Jag Capital Management sold 312 Tvardi Therapeutics shares in Q4 2024, an estimated $3.46K.
  • Jag Capital Management first reported a position in Tvardi Therapeutics in Q2 2023 and held it in 6 quarters.
  • Jag Capital Management's Tvardi Therapeutics position peaked at $31.8K in Q2 2023.
  • 43 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2024.

Based on Jag Capital Management's 13F filing for Q4 2024, filed 6 Feb 2025.